ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2031³â)
Autoimmune Disease Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
ÁÖ¿ä ÀλçÀÌÆ®
- ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå ±Ô¸ð : 60¾ï ´Þ·¯(2024³â)
- ¿¹»ó ½ÃÀå ±Ô¸ð : 126¾ï ´Þ·¯(2031³â)
- ¼¼°è ½ÃÀå ¼ºÀå·ü : 9.2%(2024-2031³â CAGR)
ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå - Á¶»ç ¹üÀ§
ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀåÀº ·ù¸¶Æ¼½º °üÀý¿°, ·çǪ½º, ´Ù¹ß¼º °æÈÁõ°ú °°Àº Áõ»óÀ» Æ÷ÇÔÇÑ ÀÚ°¡¸é¿ªÁúȯÀ» °¨ÁöÇÏ´Â µ¥ »ç¿ëµÇ´Â Áø´Ü ¼ºñ½º ¹× °Ë»ç¸¦ ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â ÀÚ°¡¸é¿ªÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÏ°í °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, ȯÀÚ¿¡°Ô ¸ÂÃãÇü Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀå ÃËÁø¿äÀÎÀº ÀÚ°¡ ¸é¿ª ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü °Ë»ç ¹æ¹ýÀÇ ±â¼ú ¹ßÀüÀÔ´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ Áø´ÜÀ» Á¦°øÇÏ´Â µ¥ ÁßÁ¡À» µÎ¾î ÀÓ»ó ¹× ÀçÅà Áø·á ¸ðµÎ¿¡¼ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
ÀÚ°¡¸é¿ªÁúȯ À¯º´·ü Áõ°¡, Áø´Ü ±â¼ú ¹ßÀü, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀÎÀÌ ¼¼°è ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶ó °³¼±À¸·Î Á¤È®Çϰí È¿À²ÀûÀÎ °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºÐÀÚÁø´Ü ¹× ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý °Ë»ç¿Í °°Àº ÷´Ü Áø´Ü µµ±¸ÀÇ Ã¤ÅÃÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Àü¹® °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇÏ´Â ¿äÀÎÀÔ´Ï´Ù.
½ÃÀå ¾ïÁ¦¿äÀÎ
ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀåÀº ¼ºÀå ÀáÀç·Â¿¡µµ ºÒ±¸Çϰí, ÷´Ü Áø´Ü °Ë»çÀÇ ³ôÀº ºñ¿ë°ú °Ë»ç ÀýÂ÷ÀÇ Ç¥ÁØÈ ºÎÁ· µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯÀº ´Ù¸¥ Áúȯ°ú Áߺ¹µÇ´Â °æ¿ì°¡ ¸¹¾Æ Áø´ÜÀÌ ¾î·Æ°í, °Ë»çÀÇ Á¤È®¼º°ú ÇØ¼®¿¡ ¾î·Á¿òÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³¹ßµµ»ó±¹¿¡¼´Â ÷´Ü Áø´Ü µµ±¸¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÖ°í, °Ë»ç ºñ¿ëÀÌ ºñ½Î´Ù´Â Á¡µµ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ À庮°ú °Ë»ç ¹æ¹ýÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀÇ Çʿ伺µµ ¾÷°è °ü°èÀڵ鿡°Ô µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ
ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀåÀº Á¶±â Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä, ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸ÀÇ ¹ßÀü, º¸´Ù Àú·ÅÇÑ °Ë»ç ¼Ö·ç¼ÇÀÇ °³¹ß µîÀ¸·Î ÀÎÇØ Å« ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í Àü¹® °Ë»ç ¼ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ·á ¼ºñ½º Á¦°øÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ±â¾÷µé¿¡°Ô ±âȸ°¡ µÉ °ÍÀÔ´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö´Â ½ÅÈï ½ÃÀå ÁøÃâÀº »õ·Î¿î ¼ºÀåÀÇ ±æÀ» Á¦½ÃÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÇ·á Á¦°øÀÚ ¹× º¸Çè»ç¿ÍÀÇ Àü·«Àû Á¦ÈÞ´Â °Ë»ç ¼ºñ½º¸¦ º¸´Ù Ä£¼÷Çϰí Àú·ÅÇÏ°Ô ¸¸µé¾î °í°´ ±â¹ÝÀ» È®´ëÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ¼¼°è ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÏ¿© ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ, °úÁ¦ µî ½ÃÀå ¿ªÇÐ ºÐ¼®°ú ½ÃÀå »óȲ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
- ½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- °úÁ¦
- ÁÖ¿ä µ¿Çâ
- °Å½Ã°æÁ¦ ¿äÀÎ
- ¼¼°èÀÇ ºÎ¹® Àü¸Á
- ¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
- COVID-19ÀÇ ¿µÇ⠺м®
- ¿¹Ãø¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
- Á¦Ç° ä¿ë ºÐ¼®
- ±â¼ú Æò°¡
- ±ÔÁ¦ »óȲ
- ¹ë·ùüÀÎ ºÐ¼®
- ÁÖ¿ä °Å·¡¿Í ÇÕº´
- PESTLE ºÐ¼®
- Porter's Five Forces ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2024-2031³â)
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ½ÃÀå ±Ô¸ð¿Í Àü³âºñ ¼ºÀå
- Àý´ëÀû ¼öÀÍ ±âȸ
- ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼®(2019-2023³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø(2024-2031³â)
- ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : Á¦Ç° À¯Çü
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : Á¦Ç° À¯Çüº°(2019-2023³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°(2024-2031³â)
- ½ÃÀå ¸Å·Â ºÐ¼® : Á¦Ç° À¯Çü
- ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : Áúȯ À¯Çü
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : Áúº´ À¯Çüº°(2019-2023³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áúȯ À¯Çüº°(2024-2031³â)
- ½ÃÀå ¸Å·Â ºÐ¼® : Áúº´ Á¾·ù
- ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : °Ë»ç À¯Çü
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : °Ë»ç À¯Çüº°(2019-2023³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : °Ë»ç À¯Çüº°(2024-2031³â)
- ½ÃÀå ¸Å·Â ºÐ¼® : °Ë»ç À¯Çü
- ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚ
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°(2019-2023³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024-2031³â)
- ½ÃÀå ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚ
Á¦5Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : Áö¿ª
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : Áö¿ªº°(2019-2023³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°(2024-2031³â)
- ºÏ¹Ì
- À¯·´
- µ¿¾Æ½Ã¾Æ
- ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ª
Á¦6Àå ºÏ¹ÌÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : °ú°Å(2019-2024³â)¿Í ¿¹Ãø(2024-2031³â)
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- °¡°Ý ºÐ¼®
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ½ÃÀ庰(2019-2023³â)
- ±¹°¡º°
- Á¦Ç° À¯Çüº°
- Áúȯ À¯Çüº°
- °Ë»ç À¯Çüº°
- ÃÖÁ¾»ç¿ëÀÚº°
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áúȯ À¯Çüº°(2024-2031³â)
- Àü½ÅÈ«¹Ý·çǪ½º
- °æÇÇÁõ
- Ç÷°ü¿°
- ¿°Áõ¼º ÀåÁúȯ
- ·ù¸¶Æ¼½º °üÀý¿°
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : °Ë»ç À¯Çüº°(2024-2031³â)
- ¿°Áõ ¸¶Ä¿
- Á¤±âÀûÀÎ ÀÓ»ó °Ë»ç
- Ç×»çÀÏ·Î ±Û·Îºí¸° Ç×ü
- Ç×ü, ¸é¿ªÇÐ °Ë»ç
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024-2031³â)
- º´¿ø¡¤Áø·á¼Ò
- Áø´Ü °Ë»ç½Ç
- ¿¬±¸½Ç
- ±âŸ
- ½ÃÀå ¸Å·Â ºÐ¼®
Á¦7Àå À¯·´ÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2024-2031³â)
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ½ÃÀ庰(2019-2023³â)
- ±¹°¡º°
- Á¦Ç° À¯Çüº°
- Áúȯ À¯Çüº°
- °Ë»ç À¯Çüº°
- ÃÖÁ¾»ç¿ëÀÚº°
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áúȯ À¯Çüº°(2024-2031³â)
- Àü½ÅÈ«¹Ý·çǪ½º
- °æÇÇÁõ
- Ç÷°ü¿°
- ¿°Áõ¼º ÀåÁúȯ
- ·ù¸¶Æ¼½º °üÀý¿°
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : °Ë»ç À¯Çüº°(2024-2031³â)
- ¿°Áõ ¸¶Ä¿
- Á¤±âÀûÀÎ ÀÓ»ó °Ë»ç
- Ç×»çÀÏ·Î ±Û·Îºí¸° Ç×ü
- Ç×ü, ¸é¿ªÇÐ °Ë»ç
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024-2031³â)
- º´¿ø¡¤Áø·á¼Ò
- Áø´Ü °Ë»ç½Ç
- ¿¬±¸½Ç
- ±âŸ
- ½ÃÀå ¸Å·Â ºÐ¼®
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2024-2031³â)
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ½ÃÀ庰(2019-2023³â)
- ±¹°¡º°
- Á¦Ç° À¯Çüº°
- Áúȯ À¯Çüº°
- °Ë»ç À¯Çüº°
- ÃÖÁ¾»ç¿ëÀÚº°
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áúȯ À¯Çüº°(2024-2031³â)
- Àü½ÅÈ«¹Ý·çǪ½º
- °æÇÇÁõ
- Ç÷°ü¿°
- ¿°Áõ¼º ÀåÁúȯ
- ·ù¸¶Æ¼½º °üÀý¿°
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : °Ë»ç À¯Çüº°(2024-2031³â)
- ¿°Áõ ¸¶Ä¿
- Á¤±âÀûÀÎ ÀÓ»ó °Ë»ç
- Ç×»çÀÏ·Î ±Û·Îºí¸° Ç×ü
- Ç×ü, ¸é¿ªÇÐ °Ë»ç
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024-2031³â)
- º´¿ø¡¤Áø·á¼Ò
- Áø´Ü °Ë»ç½Ç
- ¿¬±¸½Ç
- ±âŸ
- ½ÃÀå ¸Å·Â ºÐ¼®
Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2024-2031³â)
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ½ÃÀ庰(2019-2023³â)
- ±¹°¡º°
- Á¦Ç° À¯Çüº°
- Áúȯ À¯Çüº°
- °Ë»ç À¯Çüº°
- ÃÖÁ¾»ç¿ëÀÚº°
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°(2024-2031³â)
- Àεµ
- µ¿³²¾Æ½Ã¾Æ
- È£ÁÖ
- ±âŸ ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áúȯ À¯Çüº°(2024-2031³â)
- Àü½ÅÈ«¹Ý·çǪ½º
- °æÇÇÁõ
- Ç÷°ü¿°
- ¿°Áõ¼º ÀåÁúȯ
- ·ù¸¶Æ¼½º °üÀý¿°
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : °Ë»ç À¯Çüº°(2024-2031³â)
- ¿°Áõ ¸¶Ä¿
- Á¤±âÀûÀÎ ÀÓ»ó °Ë»ç
- Ç×»çÀÏ·Î ±Û·Îºí¸° Ç×ü
- Ç×ü, ¸é¿ªÇÐ °Ë»ç
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024-2031³â)
- º´¿ø¡¤Áø·á¼Ò
- Áø´Ü °Ë»ç½Ç
- ¿¬±¸½Ç
- ±âŸ
- ½ÃÀå ¸Å·Â ºÐ¼®
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2024-2031³â)
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ½ÃÀ庰(2019-2023³â)
- ±¹°¡º°
- Á¦Ç° À¯Çüº°
- Áúȯ À¯Çüº°
- °Ë»ç À¯Çüº°
- ÃÖÁ¾»ç¿ëÀÚº°
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°(2024-2031³â)
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áúȯ À¯Çüº°(2024-2031³â)
- Àü½ÅÈ«¹Ý·çǪ½º
- °æÇÇÁõ
- Ç÷°ü¿°
- ¿°Áõ¼º ÀåÁúȯ
- ·ù¸¶Æ¼½º °üÀý¿°
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : °Ë»ç À¯Çüº°(2024-2031³â)
- ¿°Áõ ¸¶Ä¿
- Á¤±âÀûÀÎ ÀÓ»ó °Ë»ç
- Ç×»çÀÏ·Î ±Û·Îºí¸° Ç×ü
- Ç×ü, ¸é¿ªÇÐ °Ë»ç
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024-2031³â)
- º´¿ø¡¤Áø·á¼Ò
- Áø´Ü °Ë»ç½Ç
- ¿¬±¸½Ç
- ±âŸ
- ½ÃÀå ¸Å·Â ºÐ¼®
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÚ°¡¸é¿ªÁúȯ °Ë»ç ½ÃÀå Àü¸Á : °ú°Å(2019-2023³â)¿Í ¿¹Ãø(2024-2031³â)
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : ½ÃÀ庰(2019-2023³â)
- ±¹°¡º°
- Á¦Ç° À¯Çüº°
- Áúȯ À¯Çüº°
- °Ë»ç À¯Çüº°
- ÃÖÁ¾»ç¿ëÀÚº°
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ±¹°¡º°(2024-2031³â)
- GCC ±¹°¡
- ÀÌÁýÆ®
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ºÏ¾ÆÇÁ¸®Ä«
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°(2024-2031³â)
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áúȯ À¯Çüº°(2024-2031³â)
- Àü½ÅÈ«¹Ý·çǪ½º
- °æÇÇÁõ
- Ç÷°ü¿°
- ¿°Áõ¼º ÀåÁúȯ
- ·ù¸¶Æ¼½º °üÀý¿°
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : °Ë»ç À¯Çüº°(2024-2031³â)
- ¿°Áõ ¸¶Ä¿
- Á¤±âÀûÀÎ ÀÓ»ó °Ë»ç
- Ç×»çÀÏ·Î ±Û·Îºí¸° Ç×ü
- Ç×ü, ¸é¿ªÇÐ °Ë»ç
- ±âŸ
- ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024-2031³â)
- º´¿ø¡¤Áø·á¼Ò
- Áø´Ü °Ë»ç½Ç
- ¿¬±¸½Ç
- ±âŸ
- ½ÃÀå ¸Å·Â ºÐ¼®
Á¦12Àå °æÀï ±¸µµ
- ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
- ½ÃÀå ±¸Á¶
- °æÀï °µµ ¸Ê : ½ÃÀ庰
- °æÀï ´ë½Ãº¸µå
- ±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±ÙÀÇ µ¿Çâ)
- Abbott Laboratories
- Thermo Fisher Scientific
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers
- Bio-Rad Laboratories
- Beckman Coulter(Danaher Corporation)
- Quest Diagnostics
- PerkinElmer, Inc.
- Hologic, Inc.
- Grifols
- bioMerieux
- Werfen(Inova Diagnostics)
- Ortho Clinical Diagnostics
- Trinity Biotech
- EUROIMMUN(A PerkinElmer Company)
Á¦13Àå ºÎ·Ï
ksm
Persistence Market Research has recently released a comprehensive report on the global Autoimmune Disease Testing Market, offering an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report provides valuable insights into the market landscape, aiding stakeholders in making informed decisions.
Key Insights:
- Autoimmune Disease Testing Market Size (2024E): US$ 6 Bn
- Projected Market Value (2031F): US$ 12.6 Bn
- Global Market Growth Rate (CAGR 2024 to 2031): 9.2%
Autoimmune Disease Testing Market - Report Scope:
The Autoimmune Disease Testing market refers to the diagnostic services and tests used to detect autoimmune diseases, including conditions such as rheumatoid arthritis, lupus, and multiple sclerosis. These tests are essential in the early detection and management of autoimmune disorders, offering personalized treatment options for patients. The market is driven by the rising prevalence of autoimmune diseases, growing awareness about early diagnosis, and technological advancements in diagnostic testing methods. These tests are used in both clinical and homecare settings, with a focus on providing accurate and timely diagnosis.
Market Growth Drivers:
Several factors are contributing to the growth of the global Autoimmune Disease Testing market, including the increasing prevalence of autoimmune diseases, advancements in diagnostic technologies, and a growing demand for personalized medicine. Additionally, the rise in healthcare expenditure, along with improvements in healthcare infrastructure, is boosting the demand for accurate and efficient testing methods. The adoption of advanced diagnostic tools, such as molecular diagnostics and biomarker-based tests, is further accelerating market growth. Increasing awareness about autoimmune diseases and the availability of specialized tests are also factors supporting the market's expansion.
Market Restraints:
Despite its growth potential, the Autoimmune Disease Testing market faces challenges, including the high cost of advanced diagnostic tests and the lack of standardization in testing procedures. The complexity of autoimmune diseases, which often overlap with other conditions, can make diagnosis difficult, leading to challenges in test accuracy and interpretation. Furthermore, limited access to advanced diagnostic tools in developing regions, coupled with the high costs of such tests, may inhibit market growth. Additionally, regulatory hurdles and the need for continuous innovation in testing methodologies pose challenges to industry players.
Market Opportunities:
The Autoimmune Disease Testing market presents significant opportunities, driven by the demand for early-stage diagnosis, advancements in biomarker research, and the development of more affordable testing solutions. The rising focus on precision medicine and the increasing number of healthcare providers offering specialized testing services create opportunities for market players. Expansion into emerging markets, where awareness about autoimmune diseases is growing, presents new avenues for growth. Moreover, strategic partnerships with healthcare providers and insurance companies could help make testing services more accessible and affordable, thereby expanding the customer base.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the global Autoimmune Disease Testing market?
- Which diagnostic methods and test types are leading the market in terms of demand and revenue?
- How are technological advancements, such as molecular diagnostics, influencing the autoimmune disease testing industry?
- Who are the leading players in the Autoimmune Disease Testing market, and what strategies are they employing to maintain their market positions?
- What are the emerging trends and future prospects in the global Autoimmune Disease Testing market?
Competitive Intelligence and Business Strategy:
Leading companies in the global Autoimmune Disease Testing market, such as Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, are focusing on expanding their diagnostic test portfolios, improving testing accuracy, and enhancing the speed of results. These companies are investing in research and development to introduce new, more efficient diagnostic tools while also expanding their geographic reach through collaborations with healthcare institutions. Partnerships with insurance companies and healthcare providers are crucial for enhancing service accessibility and ensuring long-term market growth. Furthermore, a focus on regulatory compliance, product innovation, and service quality is key to maintaining a competitive edge in the industry.
Key Companies Profiled:
- Abbott Laboratories
- Thermo Fisher Scientific
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers
- Bio-Rad Laboratories
- Beckman Coulter (Danaher Corporation)
- Quest Diagnostics
- PerkinElmer, Inc.
- Hologic, Inc.
- Grifols
- bioMerieux
- Werfen (Inova Diagnostics)
- Ortho Clinical Diagnostics
- Trinity Biotech
- EUROIMMUN (A PerkinElmer Company)
Autoimmune Disease Testing Industry Segmentation
By Product Type
- Instruments
- Reagents and Consumables
By Disease Type
- Systemic Lupus Erythematosus
- Scleroderma
- Vasculitis
- Inflammatory Bowel Disease
- Rheumatoid Arthritis
By Test Type
- Inflammatory Markers
- Routine Laboratory Tests
- Anti-Thyroglobulin Antibody
- Antibodies and Immunology Test
By End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Research Laboratories
By Region
- North America
- Europe
- East Asia
- South Asia and Oceania
- Latin America
- The Middle East and Africa
Table of Contents
1. Executive Summary
- 1.1. Global Autoimmune Disease Testing Market Snapshot, 2024 - 2031
- 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
- 3.1. Product Adoption Analysis
- 3.2. Technology Assessment
- 3.3. Regulatory Landscape
- 3.4. Value Chain Analysis
- 3.5. Key Deals and Mergers
- 3.6. PESTLE Analysis
- 3.7. Porter's Five Force Analysis
4. Global Autoimmune Disease Testing Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
- 4.3. Global Autoimmune Disease Testing Market Outlook: Product Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2023
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 4.3.3.1. Instruments
- 4.3.3.2. Reagents & Consumables
- 4.4. Market Attractiveness Analysis: Product Type
- 4.5. Global Autoimmune Disease Testing Market Outlook: Disease Type
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Disease Type, 2019 - 2023
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024 - 2031
- 4.5.3.1. Systemic Lupus Erythematosus
- 4.5.3.2. Scleroderma
- 4.5.3.3. Vasculitis
- 4.5.3.4. Inflammatory Bowel Disease
- 4.5.3.5. Rheumatoid Arthritis
- 4.5.3.6. Others
- 4.6. Market Attractiveness Analysis: Disease Type
- 4.7. Global Autoimmune Disease Testing Market Outlook: Test Type
- 4.7.1. Introduction / Key Findings
- 4.7.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019 - 2023
- 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024 - 2031
- 4.7.3.1. Inflammatory Markers
- 4.7.3.2. Routine Laboratory Tests
- 4.7.3.3. Anti-Thyroglobulin Antibody
- 4.7.3.4. Antibodies and Immunology Test
- 4.7.3.5. Others
- 4.8. Market Attractiveness Analysis: Test Type
- 4.9. Global Autoimmune Disease Testing Market Outlook: End User
- 4.9.1. Introduction / Key Findings
- 4.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
- 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 4.9.3.1. Hospitals & Clinics
- 4.9.3.2. Diagnostic Laboratories
- 4.9.3.3. Research Laboratories
- 4.9.3.4. Others
- 4.10. Market Attractiveness Analysis: End User
5. Global Autoimmune Disease Testing Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
- 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024 - 2031
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.4. Market Attractiveness Analysis: Region
6. North America Autoimmune Disease Testing Market Outlook: Historical (2019 - 2024) and Forecast (2024 - 2031)
- 6.1. Key Highlights
- 6.2. Pricing Analysis
- 6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 6.3.1. By Country
- 6.3.2. By Product Type
- 6.3.3. By Disease Type
- 6.3.4. By Test Type
- 6.3.5. By End User
- 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 6.4.1. U.S.
- 6.4.2. Canada
- 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 6.5.1. Instruments
- 6.5.2. Reagents & Consumables
- 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024 - 2031
- 6.6.1. Systemic Lupus Erythematosus
- 6.6.2. Scleroderma
- 6.6.3. Vasculitis
- 6.6.4. Inflammatory Bowel Disease
- 6.6.5. Rheumatoid Arthritis
- 6.6.6. Others
- 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024 - 2031
- 6.7.1. Inflammatory Markers
- 6.7.2. Routine Laboratory Tests
- 6.7.3. Anti-Thyroglobulin Antibody
- 6.7.4. Antibodies and Immunology Test
- 6.7.5. Others
- 6.8. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 6.8.1. Hospitals & Clinics
- 6.8.2. Diagnostic Laboratories
- 6.8.3. Research Laboratories
- 6.8.4. Others
- 6.9. Market Attractiveness Analysis
7. Europe Autoimmune Disease Testing Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 7.2.1. By Country
- 7.2.2. By Product Type
- 7.2.3. By Disease Type
- 7.2.4. By Test Type
- 7.2.5. By End User
- 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 7.3.1. U.S.
- 7.3.2. Canada
- 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 7.4.1. Instruments
- 7.4.2. Reagents & Consumables
- 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024 - 2031
- 7.5.1. Systemic Lupus Erythematosus
- 7.5.2. Scleroderma
- 7.5.3. Vasculitis
- 7.5.4. Inflammatory Bowel Disease
- 7.5.5. Rheumatoid Arthritis
- 7.5.6. Others
- 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024 - 2031
- 7.6.1. Inflammatory Markers
- 7.6.2. Routine Laboratory Tests
- 7.6.3. Anti-Thyroglobulin Antibody
- 7.6.4. Antibodies and Immunology Test
- 7.6.5. Others
- 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 7.7.1. Hospitals & Clinics
- 7.7.2. Diagnostic Laboratories
- 7.7.3. Research Laboratories
- 7.7.4. Others
- 7.8. Market Attractiveness Analysis
8. East Asia Autoimmune Disease Testing Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 8.2.1. By Country
- 8.2.2. By Product Type
- 8.2.3. By Disease Type
- 8.2.4. By Test Type
- 8.2.5. By End User
- 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 8.4.1. Instruments
- 8.4.2. Reagents & Consumables
- 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024 - 2031
- 8.5.1. Systemic Lupus Erythematosus
- 8.5.2. Scleroderma
- 8.5.3. Vasculitis
- 8.5.4. Inflammatory Bowel Disease
- 8.5.5. Rheumatoid Arthritis
- 8.5.6. Others
- 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024 - 2031
- 8.6.1. Inflammatory Markers
- 8.6.2. Routine Laboratory Tests
- 8.6.3. Anti-Thyroglobulin Antibody
- 8.6.4. Antibodies and Immunology Test
- 8.6.5. Others
- 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 8.7.1. Hospitals & Clinics
- 8.7.2. Diagnostic Laboratories
- 8.7.3. Research Laboratories
- 8.7.4. Others
- 8.8. Market Attractiveness Analysis
9. South Asia & Oceania Autoimmune Disease Testing Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 9.2.1. By Country
- 9.2.2. By Product Type
- 9.2.3. By Disease Type
- 9.2.4. By Test Type
- 9.2.5. By End User
- 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
- 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 9.4.1. Instruments
- 9.4.2. Reagents & Consumables
- 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024 - 2031
- 9.5.1. Systemic Lupus Erythematosus
- 9.5.2. Scleroderma
- 9.5.3. Vasculitis
- 9.5.4. Inflammatory Bowel Disease
- 9.5.5. Rheumatoid Arthritis
- 9.5.6. Others
- 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024 - 2031
- 9.6.1. Inflammatory Markers
- 9.6.2. Routine Laboratory Tests
- 9.6.3. Anti-Thyroglobulin Antibody
- 9.6.4. Antibodies and Immunology Test
- 9.6.5. Others
- 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 9.7.1. Hospitals & Clinics
- 9.7.2. Diagnostic Laboratories
- 9.7.3. Research Laboratories
- 9.7.4. Others
- 9.8. Market Attractiveness Analysis
10. Latin America Autoimmune Disease Testing Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 10.2.1. By Country
- 10.2.2. By Product Type
- 10.2.3. By Disease Type
- 10.2.4. By Test Type
- 10.2.5. By End User
- 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
- 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 10.4.1. Instruments
- 10.4.2. Reagents & Consumables
- 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024 - 2031
- 10.5.1. Systemic Lupus Erythematosus
- 10.5.2. Scleroderma
- 10.5.3. Vasculitis
- 10.5.4. Inflammatory Bowel Disease
- 10.5.5. Rheumatoid Arthritis
- 10.5.6. Others
- 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024 - 2031
- 10.6.1. Inflammatory Markers
- 10.6.2. Routine Laboratory Tests
- 10.6.3. Anti-Thyroglobulin Antibody
- 10.6.4. Antibodies and Immunology Test
- 10.6.5. Others
- 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 10.7.1. Hospitals & Clinics
- 10.7.2. Diagnostic Laboratories
- 10.7.3. Research Laboratories
- 10.7.4. Others
- 10.8. Market Attractiveness Analysis
11. Middle East & Africa Autoimmune Disease Testing Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 11.2.1. By Country
- 11.2.2. By Product Type
- 11.2.3. By Disease Type
- 11.2.4. By Test Type
- 11.2.5. By End User
- 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
- 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
- 11.4.1. Instruments
- 11.4.2. Reagents & Consumables
- 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024 - 2031
- 11.5.1. Systemic Lupus Erythematosus
- 11.5.2. Scleroderma
- 11.5.3. Vasculitis
- 11.5.4. Inflammatory Bowel Disease
- 11.5.5. Rheumatoid Arthritis
- 11.5.6. Others
- 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024 - 2031
- 11.6.1. Inflammatory Markers
- 11.6.2. Routine Laboratory Tests
- 11.6.3. Anti-Thyroglobulin Antibody
- 11.6.4. Antibodies and Immunology Test
- 11.6.5. Others
- 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024 - 2031
- 11.7.1. Hospitals & Clinics
- 11.7.2. Diagnostic Laboratories
- 11.7.3. Research Laboratories
- 11.7.4. Others
- 11.8. Market Attractiveness Analysis
12. Competition Landscape
- 12.1. Market Share Analysis, 2024
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Abbott Laboratories
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Products
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Thermo Fisher Scientific
- 12.3.3. F. Hoffmann-La Roche Ltd
- 12.3.4. Siemens Healthineers
- 12.3.5. Bio-Rad Laboratories
- 12.3.6. Beckman Coulter (Danaher Corporation)
- 12.3.7. Quest Diagnostics
- 12.3.8. PerkinElmer, Inc.
- 12.3.9. Hologic, Inc.
- 12.3.10. Grifols
- 12.3.11. bioMerieux
- 12.3.12. Werfen (Inova Diagnostics)
- 12.3.13. Ortho Clinical Diagnostics
- 12.3.14. Trinity Biotech
- 12.3.15. EUROIMMUN (A PerkinElmer Company)
13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations